Cardiac amyloidosis is a growing field, with advancements in diagnosis and management. Cardiac biomarkers are used to predict survival and to develop severity staging systems. Cardiac biomarkers are also used in clinical practice to stratify patients for treatment and to evaluate response to therapies. The current review summarizes the major clinical utility of current biomarkers in patients with cardiac amyloidosis and provides insights about future areas of investigation. Display omitted •Biomarkers can be used for patients with light chain amyloidosis and transthyretin amyloidosis for staging and prognosis.•Biomarkers can be used for patients with light chain amyloidosis to determine disease progression and response to therapies.•The role of biomarkers to determine disease progression and response to therapies in patient with transthyretin amyloidosis is an active area of investigation.